Video wird geladen...
Video konnte nicht geladen werden
The MAST Program is proud to announce a Phase 2 clinical study to evaluate the next-generation compound designed to target the small intestinal microbiome. Building on the science of rifaximin, this new compound is being studied at Cedars-Sinai as a potential treatment for irritable bowel syndrome with diarrhea (IBS-D).... show more
10,199 Aufrufe • vor 7 Monaten •via X (Twitter)
5 Kommentare

Bethvor 7 Monaten
You guys rock!

Janet Olivervor 7 Monaten
Very excited to hear more about this!

Jeffrey Roberts, MS BScvor 7 Monaten
Congrats!! Your work continues to change lives for the better.

Swamy Venuturupalli, MDvor 7 Monaten
wonderful news! Great work.

BHARATvor 7 Monaten
Great news
